RARA and acute promyelocytic leukemia: Indeed, it was reported that upon administration of arsenic in acute promyelocytic leukaemia (APL), PML-RARα fusion oncoprotein undergoes SUMOylation by small ubiquitin-like modifiers (SUMO) and are then subjected to RNF4-mediated proteasomal degradation [50], [51].